CLSI 액체배지 미량희석법, Etest 및 Minimum Fungicidal Concentration 검사에 의한 국내 혈액에서 분리된 효모균의 시험관 내 Amphotericin B 내성 성적
In Vitro Amphotericin B Susceptibility of Korean Bloodstream Yeast Isolates Assessed by the CLSI Broth Microdilution Method, Etest, and Minimum Fungicidal Concentration Test
2
조회
0
다운로드
5
인용
0
참고문헌
초록
Abstract
Background : Although amphotericin B (AMB) has a wide spectrum of activity that encompasses the majority of yeast isolates, there have been recent reports suggesting that some yeast isolates exhibit decreased susceptibility to AMB. However, in vitro AMB susceptibility of yeast species isolates from blood cultures in Korea has not been fully surveyed. Methods : A total of 92 bloodstream yeast isolates from four Korean hospitals, representing 10 Candida species (69 isolates) and 4 non-Candida yeast species (23 isolates) were evaluated. AMB minimum inhibitory concentrations (MICs) were determined by two methods: the CLSI method and Etest. AMB minimum fungicidal concentrations (MFCs) were also determined. Results : For all 92 yeast isolates, the CLSI method generated a restricted range of MICs (0.125 to 4 μg/mL) with 3.3% exhibiting MICs ≥2 μg/mL, and the corresponding MFC values ranged from 0.25 to 8 μg/mL with 26.1% showing MFCs ≥2 μg/mL. Etest produced the widest distribution of MICs, ranging from 0.03 to 32 μg/mL. High AMB MICs (≥0.38 μg/mL) by Etest was observed in 34.8% of the isolates: Candida krusei (100%), Candida rugosa (100%), Trichosporon asashii (100%), Candida glabrata (82%), and Yarrowia lipolytica (75%). Etest disclosed that all isolates of Candida guilliermondii, Candida lusitaniae, Candida pelliculosa and Kodamaea ohmeri were highly susceptible to AMB (MIC ≤0.19 μg/mL). Conclusions : Our study showed that Etest may be more useful to discriminate yeast isolates with reduced susceptibility to AMB, and some isolates of less common yeast species from Korea may have decreased AMB susceptibilities. (Korean J Lab Med 2008;28:346-52)
참고문헌 (20)
- Ghannoum MA, "Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance", Clin Microbiol Rev, 12, pp.501~517 (1999)
- "Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2002", ~ (2002)
- Antoniadou A, "Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy", Medicine, 82, pp.309~321 (2003)
- Nguyen MH, "Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia", J Infect Dis, 177, pp.425~430 (1998)
- Wanger A, "Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates", Antimicrob Agents Chemother, 39, pp.2520~2522 (1995)
- Arendrup M, "Comparison of Etest and a tablet diffusion test with the NCCLS broth microdilution method for fluconazole and amphotericin B susceptibility testing of Candida isolates", J Antimicob Chemother, 47, pp.521~5216 (2001)
- Clancy CJ, "Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia", Antimicrob Agents Chemother, 43, pp.1289~1290 (1999)
- Peyron F, "Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest", J Clin Microbiol, 39, pp.339~342 (2001)
- Pappas PG, "Guidelines for treatment of candidi", Clin Infect Dis, 38, pp.161~189 (2004)
- Park BJ, "Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome", Antimicrob Agents Chemother, 50, pp.1287~1292 (2006)
- Pfaller MA, "Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus", J Clin Microbiol, 42, pp.4419~4431 (2004)
- Kim M, "E-test for antifungal susceptibility testing of Candida species", Korean J Clin Pathol, 19, pp.78~85 (1999)
- Pfaller MA, "Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B", Diagn Microbiol Infect Dis, 32, pp.223~227 (1998)
- Johnson EM, "Comparison of in vitro antifungal activities of free and liposomeencapsulated nystatin with those of four amphotericin B formulations", Antimicrob Agents Chemother, 42, pp.1412~1416 (1998)
- Canton E, "Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species", Diagn Microbiol Infect Dis, 45, pp.203~206 (2003)
- Arikan S, "Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asashii isolates", Diagn Microbiol Infect Dis, 43, pp.107~111 (2002)
- Koc AN, "Comparison of E-test with the broth microdilution method in susceptibility testing of yeast isolates against four antifungals", Mycoses, 43, pp.293~297 (2000)
- Lee JS, "Kodamaea ohmeri isolates from patients in a university hospital:identification, antifungal susceptibility, and pulsed-field gel electrophoresis analysis", J Clin Microbiol, 45, pp.1005~1010 (2007)
- Belet N, "Caspofungin treatment in two infants with persistent fungaemia due to Candida lipolytica", Scand J Infect Dis, 38, pp.559~562 (2006)
- Rodriguez-Tudela JL, "Susceptibility patterns and molecular identification of Trichosporon species", Antimicrob Agents Chemother, 49, pp.4026~4034 (2005)